Where are you?
To give you the most accurate information about our products and what we can do for you, we need to direct you to the right site.
MagnetOs for predictable fusions
the current % rate of non-unions.1,2
the current % rate of revision surgeries needed.3
the % fusion rate that can be improved by choosing the most effective bone graft.2,4,5
A bone graft like no other
MagnetOs isn’t like other bone grafts. It grows bone even in soft tissue thanks to our unique NeedleGrip™ surface technology which provides traction for our body’s vitally important ‘pro-healing’ immune cells (M2 macrophages).*†6,7
This in turn, unlocks previously untapped potential to stimulate stem cells – and form new bone throughout the graft.*8-10
The growing body of science behind NeedleGrip is called osteoimmunology. But for surgeons and their patients it means one thing: a more efficient and predictable fusion.*‡10
MagnetOs:
the evidence
MagnetOs is proven to be equivalent to the gold standard of autograft for spinal fusions.8-10 It has been used in more than 5,000 successful spinal fusion surgeries to date, and is supported by an unprecedented blend of scientific, pre-clinical and clinical studies through Project Fusion: our global research program, where science and clinical evidence meet.
Kuros is the first and only company to reliably translate evidence from benchtop through to patient. Watch these 5 videos to see how.
What people are saying about MagnetOs
Want to learn more about MagnetOs?
Book your own appointment with one of our scientific experts.
Suggested Reading
References And Disclaimers
Discover the latest data which describes the evidence for M2 macrophage upregulation by MagnetOs, all the way from benchtop to the clinic, on eCM Journal
MoreDiscover more of our research for MagnetOs bone graft on Pubmed.gov
MoreSee selected articles in the field of osteoimmunology on Pubmed.gov
MoreFind the latest data on posterolateral spine fusion rates for each category of bone graft on Pubmed.gov
More1. Medtech 360 report “Orthopedic Biomaterials Market Analysis 2017”.
2. Hsu, et al. GSJ. 2012;2:239–248.
3. Mabud, et al. Clin Spine Surg. 2017;30:E1376–E1381.
4. Chun, et al. Neurosurgical Focus. 2015;39(4):E10.
5. Morris, et al. ESJ. 2018;27:1856–1867.
6. Duan, et al. eCM. 2019;37:60-73.
7. Van Dijk, et al. JOR Spine . 2018;e1039.
8. Van Dijk, et al. J Biomed Mater Res. Part B: Appl Biomater. 2019;107(6):2080-2090.
9. Van Dijk, et al. eCM. 2021;41:756-73.
10. Van Dijk, et al. Clin Spine Surg. 2020;33(6):E276-E287.
PROMO/KUR/GL/062-21/R00